Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24325627 | 0.87 | CTSS (0.35) | ALDH1A1KMT2ACNR2CTSSCTSK | |
| SCHEMBL25273708 | 0.83 | KMT2A (0.48) | ALDH1A1KMT2ACTSSCTSKMEN1 | |
| SCHEMBL24326572 | 0.83 | KMT2A (0.48) | ALDH1A1KMT2ACTSSCTSKMEN1 | |
| SCHEMBL24326601 | 0.81 | ALDH1A1 (0.38) | ALDH1A1KMT2ACNR2LMNAMAPT | |
| SCHEMBL26358020 | 0.77 | ALDH1A1 (0.38) | ALDH1A1KMT2ACNR2LMNAMAPT | |
| SCHEMBL32662480 | 0.76 | CA1 (0.39) | ALDH1A1KMT2ACTSSCTSKCA12 | |
| SCHEMBL17712278 | 0.75 | PKM (0.46) | ALDH1A1KMT2AMEN1TSHRCA12 | |
| SCHEMBL24326600 | 0.74 | CYP2C9 (0.39) | ALDH1A1KMT2ACNR2MEN1LMNA | |
| SCHEMBL17987979 | 0.73 | KMT2A (0.55) | ALDH1A1KMT2ACTSKEPHX1CA1 | |
| SCHEMBL12844020 | 0.73 | KMT2A (0.55) | ALDH1A1KMT2ACTSKEPHX1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119426-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | ALDH1A1 3872/4885KMT2A 4151/4885CNR2 3522/4885 |
| US-20230303599-A1 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | PNP, TYMP, NME2 | ALDH1A1 3872/4885KMT2A 4151/4885CNR2 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.